VBL Therapeutics to Present at Upcoming Conferences
H.C. Wainwright 23rd Annual Global Investment Conference
Mon., Sept. 13, 2021
Fireside chat available on-demand beginning at 7:00 a.m. ET
Cell & Gene Therapy World Asia 2021 conference
Wed., Sept. 15, 2021
Presentation Time: 4:45 PM (SGT)
Keynote Presentation Topic: VB-111: Transformative Gene therapy with the Potential to Change the Treatment Paradigm for Solid Tumors
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Wed., Sept. 22, 2021
Fireside chat at 1:15 PM - 1:55 PM (ET).
Webcasts will be available via the Events and Presentations section of the Company’s Investor Relations page.
About VBL Therapeutics
Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer and immune or inflammatory indications. VBL has developed three platform technologies: a gene-therapy based platform for targeting newly formed blood vessels with focus on cancer, an antibody-based platform targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the lecinoxoids platform, comprised of a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111; `ofra-vec`), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent in development to treat a wide range of solid tumors. VB-111 is currently being studied in a Phase 3 registration-enabling trial for platinum-resistant ovarian cancer. To learn more about VBL Therapeutics, please visit vblrx.com or follow the company on LinkedIn, Twitter, YouTube or Facebook.
Upcoming Life Sciences Events
- October 2021
- BIO-Europe® 2021
- Online: AusBiotech 2021 & Australia Biotech Invest & Partnering
- November 2021
- Pharma-Biotech Product & Company Valuation with Dr. P Frei
Latest company news
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
NeoTX Announces First Patient Enrolled In Phase 2a Clinical Trial Of Naptumomab Estafenatox (NAP), Its Lead Tumor Targeted Superantigen (TTS) Candidate, In Combination With Docetaxel In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)